188 related articles for article (PubMed ID: 18259163)
1. Priced out of the UK market.
Moran N
Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163
[No Abstract] [Full Text] [Related]
2. The economic value of companion diagnostics and stratified medicines.
Blair ED; Stratton EK; Kaufmann M
Expert Rev Mol Diagn; 2012 Nov; 12(8):791-4. PubMed ID: 23249194
[No Abstract] [Full Text] [Related]
3. New rules for US drug reimbursement.
Bouchie A
Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382
[No Abstract] [Full Text] [Related]
4. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
Ogbighele E
IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
[TBL] [Abstract][Full Text] [Related]
5. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
Rawlins SM
Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
[No Abstract] [Full Text] [Related]
6. [Price of medications: the actual system must be seen again].
Mayencourt J
Rev Med Suisse; 2016 Mar; 12(508):479. PubMed ID: 27089613
[No Abstract] [Full Text] [Related]
7. Deconstructing Myogen's market cap.
Ransom J
Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
[No Abstract] [Full Text] [Related]
8. A change in the market--investing in diagnostics.
Batchelder K; Miller P
Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
[No Abstract] [Full Text] [Related]
9. Market watch: Top drugs and companies by sales in 2017.
Urquhart L
Nat Rev Drug Discov; 2018 Mar; 17(4):232. PubMed ID: 29588516
[No Abstract] [Full Text] [Related]
10. Value-based pricing of drugs in the UK.
Webb DJ; Walker A
Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
[No Abstract] [Full Text] [Related]
11. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
12. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
Castillo-Laborde C; Silva-Illanes N
Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
[TBL] [Abstract][Full Text] [Related]
13. Straight talk with... Mark Sculpher. Interview by Kate Ravilious.
Sculpher M
Nat Med; 2012 Sep; 18(9):1315. PubMed ID: 22961148
[TBL] [Abstract][Full Text] [Related]
14. Repackaging.
Prescrire Int; 2016 Jan; 25(167):10. PubMed ID: 26942252
[No Abstract] [Full Text] [Related]
15. Drugs cheaper than threepenny: the market of extremely low-priced drugs within the National Health Insurance in Taiwan.
Wang BR; Chou CL; Hsu CC; Chou YC; Chen TJ; Chou LF
ScientificWorldJournal; 2014; 2014():234941. PubMed ID: 24719568
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness data on biologics needed.
Sheridan C; Katsnelson A
Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
[No Abstract] [Full Text] [Related]
17. How NICE may be outflanked.
Ferner RE; McDowell SE
BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
[No Abstract] [Full Text] [Related]
18. The evolution of adaptiveness: balancing speed and evidence.
Eichler HG; Barker R; Bedlington N; Bouvy JC; Broekmans AW; Bucsics A; Cerreta F; Corriol-Rohou S; Granados A; Le Cam Y; Schuurman A
Nat Rev Drug Discov; 2018 Dec; 17(12):845-846. PubMed ID: 29977052
[No Abstract] [Full Text] [Related]
19. Getting new drugs to market: how individuals could do this without leaving their desks.
Collier J
BMJ; 2006 Dec; 333(7582):1315-7. PubMed ID: 17185722
[No Abstract] [Full Text] [Related]
20. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
Werling K; Abraham S; Strelec J
J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
